"Designing Growth Strategies is in our DNA"
Ankylosing Spondylitis is one of the commonly observed form of arthritis which causes inflammation in spine which can lead to severe chronic pain and patient discomfort. Depending on the severity and stage of the disease, inflammation in spinal bones can lead to formation of new bones in spine, this condition is called as ankyloses.
The indications of ankylosing spondylitis vary from patient to patient, however, frequent pain, stiffness in lower back and spinal discomfort are commonly observed indications of ankylosing spondylitis amongst others. According to Centres for Disease Control and Prevention (CDC), in 2012, an estimated 2.7 million populations was suffering from ankylosing spondylitis in the U.S.
At the present situation, the treatment for ankylosing spondylitis involves medications, physical therapy, surgery, exercise and good posture practices. Moreover, certain nonsteroidal anti-inflammatory drugs such as indomethacin and naproxen are highly prescribed by physicians to treat ankylosing spondylitis across the globe.
Pharmaceutical companies and research and academic institutes are prominently focusing on studying and developing new treatment options for the celiac disease. For instance; Fengshigutong, which is being studied by Sun Yat-sen University is currently in phase-4 clinical trials to check its efficacy and tolerability for the treatment of ankylosing spondylitis.
To know how our report can help streamline your business, Speak to Analyst
At present around 70% of the pipeline candidates for celiac disease are in the phase-3 and phase-4 stage. Majority of the studies have been sponsored by pharmaceutical companies and other drug manufacturers.
The report on ‘Ankylosing Spondylitis (Bekhterev’s Disease)– Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Ankylosing Spondylitis (Bekhterev’s Disease). The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Ankylosing Spondylitis (Bekhterev’s Disease).
The report on ‘Ankylosing Spondylitis (Bekhterev’s Disease)– Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.